Therapeutic Potential of Andrographolide Isolated fromthe Leaves of Andrographis paniculata Nees for TreatingLung Adenocarcinomas by Yu-Tang Tung et al.
Hindawi Publishing Corporation
Evidence-Based Complementary and Alternative Medicine
Volume 2013, Article ID 305898, 8 pages
http://dx.doi.org/10.1155/2013/305898
Research Article
Therapeutic Potential of Andrographolide Isolated from
the Leaves of Andrographis paniculata Nees for Treating
Lung Adenocarcinomas
Yu-Tang Tung,1 Hsiao-Ling Chen,2 Hsing-Chung Tsai,1,3 Shang-Hsun Yang,4
Yi-Chun Chang,1 and Chuan-Mu Chen1,5
1 Department of Life Sciences, Agricultural Biotechnology Center, National Chung Hsing University, Taichung 402, Taiwan
2Department of Bioresources, Da-Yeh University, Changhwa 515, Taiwan
3 Taichung Hospital, Department of Health, Taichung 403, Taiwan
4Department of Physiology, National Cheng Kung University, Tainan 701, Taiwan
5Department of Life Sciences, Office of Research and Development, National Chung Hsing University, No. 250,
Kuo Kuang Road, Taichung 402, Taiwan
Correspondence should be addressed to Chuan-Mu Chen; chchen1@dragon.nchu.edu.tw
Received 5 June 2013; Accepted 20 June 2013
Academic Editor: Vincenzo De Feo
Copyright © 2013 Yu-Tang Tung et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Andrographolide is one of the major diterpene lactones found in Andrographis paniculataNees and exhibits remarkable inhibitory
effects on various cancers. In this study, the antipulmonary cancer effects of andrographolide were studied in a lung tumor
mouse model induced by human vascular endothelial growth factor 𝐴
165
(hVEGF-A
165
). These results demonstrated that
andrographolide significantly reduced the expression of hVEGF-A
165
compared with a mock group in the Clara cells of the
lungs. In addition, andrographolide also decreased tumor formation by reducing VEGF, EGFR, Cyclin A, and Cyclin B expression
on the transcriptional and translational levels. These results indicated that andrographolide treatment on the overexpression of
VEGF can arrest the cell cycle, which induced pulmonary tumors in transgenic mice. In conclusion, the antiangiogenesis and
chemotherapeutic potential of andrographolide may provide a cure for pulmonary tumors in the future.
1. Introduction
According to the latest cancer mortality statistics from the
People’s Health Bureau of Taiwan, pulmonary cancer is
ranked as a leading cause of Taiwanese cancer-related deaths
[1]. Worldwide, lung cancer has been themost common form
of cancer for several decades. Although chemotherapeutic
agents for pulmonary tumors have developed, the lung
cancer death rate is still high. Thus, many researchers have
focused on early tumor detection andmore active treatments
as the tumor prevention methods [2]. For example, many
researchers have discovered useful phytochemicals (com-
pounds found in plants) and phytochemicals derivatives that
provide novel anticancer therapies that have been successfully
used in the clinic.
Andrographis paniculata Nees, a traditional medicine in
Southeastern Asian countries, has been widely used in the
clinic as an immunostimulant [3] and for the treatment of
the common cold [4], myocardial ischemia [5], pharyngo-
tonsillitis [6], and respiratory tract infections [7]. The major
component of A. paniculata is andrographolide, which has
been used to treat colds, diarrhea, fever, and inflammation,
as well as infectious diseases [8]. In addition, the chemopre-
ventive effects against and the inhibitory effects on cancer
cell growth of andrographolide have been demonstrated in
breast, colon, epidermoid, gastric, liver, leukemia, myeloma,
peripheral blood lymphocytes, and prostate cancers [9–
12]. The present study is the first to investigate whether
andrographolide treatment could inhibit the formation of
lung tumor in the hVEGF-A
165
overexpressing transgenic
mice. The airway hyperresponsiveness (AHR) was measured
during a five-month treatment ofmice with andrographolide.
In addition, the pathological histology and the hVEGF
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Andrographolide treatment: 0.125mg andrographolide was dissolved
in 10𝜇L DMSO and
Placebo treatment: 10𝜇L DMSO and
90𝜇L PBS
The treatment was injected intraperitoneally (i.p.) three times a week
AHR: the pulmonary function test was performed using saline and
12.5mg/mL methacholine
Experiments were started after the animals were raised for six months.
(b)
Figure 1: Active component of andrographolide (An) extracted from the leaves ofAndrographis paniculataNees and the animal trial timeline.
(a) Chemical structure of andrographolide. (b) The schedule of andrographolide treatment. Mice were injected intraperitoneally (i.p.) with
andrographolide (5mg/kg body weight) three times a week for 5 months, and mice were sacrificed at 11 months.
immunohistochemistry staining of the lungs of these mice
were examined.The related mRNA and protein expression in
tumorigenesis and cell cycle regulatormakerswere also tested
to evaluate the mechanism of tumor inhibition by treatment
with andrographolide.
2. Materials and Methods
2.1. Production of LungTumorTransgenicMice. Wehave gen-
erated themccsp-hVegf-A
165
-sv40 transgenicmice from pro-
nuclear microinjection technique. Homozygous (hVEGF-
A
165
+/+) or hemizygous (hVEGF-A
165
+/−) transgenic mice
were identified by genomic DNA PCR. The genomic DNA
isolated from the tails of the mice with the following primers:
VEGF-94(+): 5󸀠-AAGGAGGAGGGCAGAATCATC-3󸀠 and
VEGF-315(−): 5󸀠-GAGGTTTGATCCGCATAATCTG-3󸀠.
The exogenic human VEGF-A
165
protein and mRNA expres-
sion levels in homozygous (hVEGF-A
165
+/+) or heterozygous
(hVEGF-A
165
+/−) transgenic mice were also detected by
Western blot and RT-PCR.
2.2. Animals. A total of 12 male transgenic mice were given
with free access to water and standard laboratory diet at
a temperature- and humidity-regulated environment (22 ±
2
∘C, 65 ± 5% RH) with 12 h dark/light cycle. This study was
conducted according to institutional guidelines and approved
by the Institutional Animal Care and Utilization Committee
of National Chung-Hsing, Taiwan (IACUC no. 96-83). The
transgenicmice displaying the hemizygous (hVEGF-A
165
+/−)
genotype were randomly divided into two groups (𝑛 = 6)
based on their treatment: Tg/Mock (transgenic mice treated
with a mock or placebo) and Tg/Andrographolide (trans-
genic mice treated with andrographolide). Andrographolide
(An; Figure 1(a)) was obtained from Sigma Chemical (St.
Louis,MO,USA) and dissolved inDMSO.Mice were injected
intraperitoneally (i.p.) with andrographolide (5mg/kg body
weight) three times a week for 5 months, and mice were
sacrificed at 11 months (Figure 1(b)). Pulmonary tissues were
collected for pathological histology, immunohistochemistry
staining, RNA extraction, and protein extraction according
to our previously published protocols [13–15]. All the experi-
ments were repeated twice.
2.3. Measurement of the Airway Hyperresponsiveness (AHR).
Bronchial provocation tests that evaluate the AHR in the
Tg/Mock and Tg/Andrographolide groups were performed
using methacholine. First, the basal pulmonary function was
measured; then saline and methacholine at a concentration
of 12.5mg/mL were converted to aerosol using a nebulizer
and allowed to be inhaled five times through a Rosenthal-
French dosimeter.The pulmonary function was measured 30
times with a portable microspirometer for 3 minutes, and
the enhanced pause (penh) values were selected to represent
the pulmonary function. The penh, a dimensionless value,
represents the proportion of maximal expiratory to maximal
inspiratory box pressure signals and the timing of expiration.
The AHR was presented as the penh in response to the
increasing damage to pulmonary functionality [16].
2.4. Pathological Histology. Pulmonary tissues were fixed
in 10% buffered formaldehyde (pH 7.0), embedded with
paraffin, sectioned into 3 𝜇m sections, and examined using
hematoxylin and eosin (H&E) staining. The hematoxylin
and eosin (H&E) staining was described according to our
previous reports [17, 18].
2.5. Immunohistochemistry Staining. IHC staining of pul-
monary tissues, the VECTASTAIN ABC kit (Universal, Vec-
tor, USA)was used. Tissue sections (a thickness of 5 𝜇m)were
placed on slides and incubated overnight at 4∘C with rabbit
anti-hVEGF-A monoclonal primary antibody as previously
described [19]. Sections were developed using diaminoben-
zidine (DAB) as chromogenic substrates and counterstained
with hematoxylin [20].
2.6. Real-Time RT-PCR. RNA was extracted from lung tissue
using a Trizol reagent (Invitrogen, Carlsbad, CA) in accor-
dance with the manufacturer’s instructions. cDNA synthesis
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Figure 2: Effects of andrographolide on the airway hyperrespon-
siveness (AHR) parameters of pulmonary functionality. Data are
presented as the means ± SEM (𝑛 = 6). †𝑃 < 0.01 Tg/Mock
versus Tg/Mock group at 7 months. ∗𝑃 < 0.05 Tg/Andrographolide
group versus Tg/Mock group in the same month. ∗∗𝑃 < 0.01
Tg/Andrographolide group versus Tg/Mock group in the same
month.
reaction was performed by PCR as described for ImProm-
IITM reverse transcriptase (Promega, USA). Quantitative
real-time RT-PCR (qRT-PCR) was carried out using SYBR
Green in a Rotor-Gene 6000.The gene expressions of 14 genes
(vegf, kdr, nrp-1, myc, brca-1, mmp2, mmp9, egfr, erk2, sur-
vivin, cyclin a, cyclin b1, cyclin d, and cyclin e) were performed
on using cDNA from pulmonary tissue by qRT-PCR [21].
2.7. Western Blotting. The total protein of the pulmonary
tissues from eachmouse was homogenized in 500 𝜇L of RIPA
buffer (5mM Tris-HCl pH 7.4, 0.15M NaCl, 1% NP40, 0.25%
sodium deoxycholate, 5mM EDTA, and 1mM ethylene
glycol-bis (2-aminoethyl-ether)-N,N,N,N-tetraacetic acid)
and centrifuged at 12,000×g for 30min at 4∘C. Protein deter-
mination and Western blotting was performed according to
the procedure reported [20, 22] with slightmodifications.The
protein samples (50 𝜇g) were resolved by a 10% SDS-PAGE
and electrophoretically transferred to a PVDF membrane.
Thus, the membrane was incubated with primary antibody
(VEGF-A, EGFR, ERK2, Cyclin A, Cyclin B, or GAPDH)
overnight at 4∘Cand further incubated for 1 hwith anti-rabbit
IgG antibody conjugated to HRP. The protein expressions
were detected by the enhanced chemiluminescence reagents
(ECL).
2.8. Statistical Analysis. Statistical significance of differences
between treatments was determined by Student’s t-test. 𝑃 <
0.05 (∗) or 𝑃 < 0.01 (∗∗) were considered to be statistically
significant.
3. Results
3.1. Effects of Andrographolide on the Airway Hyperrespon-
siveness (AHR) Parameters of Pulmonary Functionality. The
mccsp-hVegf-A165-sv40 transgenic mice which induces pul-
monary tumor [16] was used as a lung cancer animal model
Table 1: Lung tumorigenesis frequency of Tg/Mock and
Tg/Andrographolide groups in the mouse lung tissues (𝑛 = 6) using
histopathological image analysis.
Variable Tg/Mock Tg/Andrographolide
Normal 0 (0%) 2 (33.3%)
Cyst 6 (100%) 4 (66.7%)
Damaged alveoli 4 (66.7%) 2 (33.3%)
Mild emphysematous change 0 (0%) 3 (50%)
Prominent emphysematous
change
6 (100%) 1 (16.7%)
Hemosiderin-laden macrophages
in alveoli
2 (33.3%) 0 (0%)
Old hemorrhage 6 (100%) 2 (33.3%)
Moderate lymphocytic
infiltration
0 (0%) 1 (16.7%)
Marked chronic lymphoid
infiltration
6 (100%) 2 (33.3%)
Neoplasm 3 (50%) 1 (16.7%)
Lymphoma 6 (100%) 1 (16.7%)
Adenocarcinoma 5 (83.3%) 2 (33.3%)
for test of andrographolide (An) therapeutic effects. The
animal trials timeline was showed in Figure 1(b). Several
invasive and noninvasive methods have been used for the
evaluation of the airway responsiveness of mice [23]. The
AHR, a noninvasive procedure, enables easily and quickly
obtainedmeasurements, and it has been an important charac-
teristic of pulmonary function. In this study, the AHR of the
andrographolide or mock treatment was measured after 7, 9,
and 11 months (Figure 2). The penh values of the Tg/Mock
treatment with methacholine were significantly increased
from 1.65 (7 months) to 3.52 (9 months), and 5.94 (11
months). However, 5mg/kg body weight of andrographolide
effectively reduced the penh elevation, exhibiting values of
1.57 (7 months), 2.28 (9 months), and 3.41 (11 months). This
result revealed that andrographolide dramatically reduced
the damage to pulmonary functionality.
3.2. Effect of Andrographolide Treatment on Lung H&E Stain-
ing and Pathological Analysis. Figure 3 and Table 1 indicate
that transgenic mice (83.3%; 5/6) have found pulmonary
tumors; these tumors primarily consisted of neoplasms
growth on the periphery of the pulmonary alveolus and
adenomas growing on the site near the lung bronchus. In
the pulmonary alveoli of the lung bronchi of the trans-
genic mice, some obvious large-grained pink cells, which
represent macrophages, are indicative of an inflammatory
response. Furthermore, the group treated with 5mg/kg
andrographolide decreased the neoplasm growing on the
periphery of the pulmonary alveolus and the adenomas grow-
ing near the site of the lung bronchus (Figures 3(c) and 3(d)).
This pathological analysis illustrated that andrographolide
has antipulmonary cancer potential (33.3%; 2/6) compared
with Tg alone (83.3%; 5/6) and induces anti-inflammatory
4 Evidence-Based Complementary and Alternative Medicine
(a)
(b)
(c)
(d)
Figure 3:The exterior, histopathological slides and immunohistochemical (IHC) staining of the lung tissues of 11-month-old transgenic mice
that overexpress hVEGF-A
165
in the (a, b) Tg/Mock group and (c, d) Tg/Andrographolide group following 5 months of andrographolide
treatment.
responses in the lungs of transgenic mice that overexpress
hVEGF-A
165
.
3.3. Effect of Andrographolide Treatment on Immunohisto-
chemistry Staining. Angiogenesis is required for the tumor
formation, tumor growth, invasion, andmetastasis. VEGF is a
principal regulator of vasculogenesis and angiogenesis. Using
immunohistochemistry staining (IHC staining), we observed
that VEGF was overexpressed in the Clara cells of lung
tissues in the transgenic mice (Figures 3(a) and 3(b)) and that
the treatment with andrographolide significantly reduced
the expression levels of VEGF (Figures 3(c) and 3(d)).
These results indicate that transgenic mice treatment with
andrographolide can decrease VEGF expression compared
with those that weremock treated; thus itmay reduce the new
blood vessel formation and growth.The anti-VEGF therapy of
andrographolide may prevent the previously observed tumor
growth, invasion, and metastasis.
3.4. Andrographolide Suppresses the Marker Genes for Tumor
Formation. The mRNA levels of vegf-a165, kdr, nrp-1, myc,
brca-1, mmp2, mmp9, egfr, erk2, survivin, cyclin a, cyclin b1,
cyclin d, and cyclin e in theTg/Mock andTg/Andrographolide
groups were evaluated using qRT-PCR (Figure 4). These
results demonstrated that treating Tg mice with 5mg/kg of
andrographolide significantly decreased the expression of
vegf-a165, kdr, nrp-1, c-myc, egfr, erk2, surviving, cyclin a,
cyclin b1, and cyclin e. Kdr and its coreceptor nrp-1, which are
the main angiogenic receptors in the vegf pathway, are down-
regulated. In addition, both the c-Myc and Ras/MEK/ERK
pathways play a vital role in the progression of the G1-cell
cycle phase by enhancing cyclins. Thus, in this study erk2
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Figure 4: Real-time PCR validations of mRNA expression levels of
vegf, kdr, nrp-1,myc, brca-1,mmp2,mmp9, egfr, erk2, survivin, cyclin
a, cyclin b1, cyclin d, and cyclin e in the lung tissues of the Tg/Mock
and Tg/Andrographolide groups. 𝛽-Actin was used as an internal
control.The quantitative mRNA expression levels weremeasured by
qRT-PCR. Data are presented as the means ± SEM (𝑛 = 6). ∗𝑃 <
0.05 versus Tg/Mock group. ∗∗𝑃 < 0.01 versus Tg/Mock group.
and c-myc down-regulation may induce cell cycle G1 arrest.
Furthermore, cyclin a is essential for c-myc-modulated cell-
cycle progression.
3.5. Andrographolide Suppresses Cell Cycle Progression Signal-
ing Pathways. VEGF, ERK2, Cyclin A, and Cyclin B were
significantly decreased in the Tg/Andrographolide group
compared with the Tg/Mock group using Western blot
analysis (Figure 5). Andrographolide affects the cell cycle by
reducing the levels of Cyclin A and Cyclin B, which regulate
the S and G2/M phases, respectively. The andrographolide-
induced downregulation of Cyclins A and B may decrease
the progression of cells through the S and G2/M phases. This
result indicates that the protein expression involved in the
S to M phase transition in transgenic mice was inhibited by
andrographolide.
4. Discussion
Previous studies have shown that Andrographis panicu-
lata possesses potent antiatherosclerotic, anti-inflammatory,
antioxidant, hepatoprotective, immunomodulatory, and anti-
cancer effects [24–29]. Andrographolide is one of the major
diterpene lactones found inA. paniculata and displays potent
anticancer and immunomodulatory effects, which may lead
to its development as a chemotherapeutic agent [28, 30]. In
addition, many researchers have demonstrated that andro-
grapholide displays excellent anticancer effects on breast,
colon, epidermoid, gastric, HeLa, liver, leukemia, myeloma,
peripheral blood lymphocytes, and prostate cancers [9–12].
Many in vitro studies demonstrated that andrographolide
promotes apoptosis in cancer cells, suppresses cancer cell
proliferation, and induces cell-cycle arrest [12, 31].
The stabilization of HIF-1𝛼 mediated the overexpression
of VEGF, which has been identified as a common step
in the development of carcinomas. Thus, VEGF-inhibitors,
which directly or indirectly target the tumor vasculature,
have become common in anticancer therapies [32]. In the
present study, we use 11-month-old transgenic mice that
overexpress a lung-specific hVEGF-A
165
. These mice contain
the mccsp-hVegf-A
165
-sv40 poly(A) transgene for research-
ing pulmonary tumors and serve as an animal model for
researching the regulatory mechanism of andrographolide.
We found that these transgenic mice are susceptible to the
growth of pulmonary tumors. However, following a 5-month
treatment with andrographolide (5mg/kg b.w. three times
a week), these mice exhibited a dramatic decrease in the
formation of solid tumors when compared with the mock
treatment. The histological examination also indicated that
the andrographolide treatment reduced pulmonary tumor
formation and inflammation (Figure 3).
Initially, the cancer cells continue to proliferate and thus
create a nutrition and oxygen deficiency, which causes signif-
icant cell death. The secretion of large quantities of VEGF-
A
165
induces vasculogenesis to provide the rapidly growing
tumor with sufficient quantities of nutrients and oxygen [33].
This solid tumor growth is dependent on angiogenesis, and
thus the suppression of tumor blood vessels offers a new
alternative to prevent and treat cancer. Using IHC staining,
we observed that andrographolide reduced the expression of
hVEGF-A
165
to normal levels, specifically in the Clara cells
in the lungs of transgenic mice. These results indicate that
andrographolide reduced the expression of VEGF in Clara
cells when compared with the mock treatment. VEGF is
essential for vasculogenesis and angiogenesis during devel-
opment and tumor progression. In addition, Zhao et al.
[34] demonstrated that andrographolide effectively inhibited
VEGF expression in prostate cancer. Lin et al. [1] found
that the inhibition of PI3 K/Akt signaling by andrographolide
significantly suppressed the protein andmRNA levels of HIF-
1𝛼, as well as the protein level and transcriptional activation
of VEGF in A549 cells. In this study, we further found that
treatment with andrographolide in lung tumor animal model
effectively reduced the expression of VEGF in tumor tissue;
this activity demonstrates that andrographolide may prove a
potent antiangiogenic agent for the treatment of pulmonary
cancer.
In addition, andrographolide can reduce pulmonary
functional damage (Figure 2) and prevent pulmonary cancer
formation through elimination of VEGF, ERK2, Cyclin A,
and Cyclin B proteins (Figure 5). Andrographolide induced
the reduction of Cyclin A and Cyclin B, which likely resulted
in the reduced progression through the S and G2/M phases.
These results indicated that andrographolide suppressed the
protein expression at the transition from the S-phase to the
M-phase in transgenic mice. These results also demonstrate
that the inhibition of the cell cycle may be a vital pathway that
andrographolide affects the transgenic mice that overexpress
VEGF. Furthermore, Satyanarayana et al. [12] revealed that
andrographolide inhibits cell-cycle arrest in MCF-7 cells by
inducing the expression of p27 (the cell-cycle inhibitory
protein) and decreasing the expression of cyclin-dependent
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Figure 5:Western blot analysis ofVEGF-A, EGFR, ERK2, CyclinA, andCyclin B protein in the lung tissues of the Tg andTg/Andrographolide
groups. GADPH was used as an internal control. Data are presented as the means ± SEM (𝑛 = 6). ∗𝑃 < 0.05 versus Tg group. ∗∗𝑃 < 0.01
versus Tg group.
KDR
ERK1/2
Nrp1KDR
VEGF
M
G1
S
G2
G0
Cyclin A
Cyclin B
Cyclin A
Cyclin E
Cyclin D1
Cyclin E
An
Cyclin A
Cyclin B
An
AnAn
An
An
An
An
An
NRP1
VEGF
Figure 6: Scheme of the andrographolide regulatory pathway. The
effects of andrographolide inhibition of lung tumors are hypothe-
sized through a cell-cycle signaling pathway.Thediagram shows that
andrographolide may inhibit VEGF-A, KDR, Nrp1, ERK2, Cyclin A,
and Cyclin B expression.
kinase. Shi et al. [31] also suggested that andrographolide
can induce cell-cycle arrest at the G1/S phase by CKI-
cyclin-Cdk signaling in Lovo cells. These results revealed
that andrographolide can induce cell-cycle arrest in cancer
cells. Furthermore, we found that erk2 downregulation was
followed by a downstream decreasing of c-myc expression
thatmay induce cell cycle arrest in the G1 phase. Additionally,
cyclin a is essential for c-myc-modulated cell-cycle progres-
sion in pulmonary cancer formation. Finally, Tsai et al. [18]
found that andrographolide inhibited chemotic migration,
which may be due to the inhibition of the ERK1/2 and
Akt protein kinase cascades. Here we show a relationship
between andrographolide treatment and the transcriptional
and translational levels of VEGF, EGFR, ERK2, and Cyclin A
(Figure 6).
5. Conclusion
The andrographolide-induced inhibition of VEGF by arrest-
ing the cell cycle may be a critical mechanism for preventing
pulmonary tumor angiogenesis and metastasis. The inhibi-
tion of VEGF by andrographolide may be a useful method
for the chemoprevention of pulmonary cancer.
Abbreviations
AHR: Airway hyperresponsiveness
An: Andrographolide
DAB: Diaminobenzidine
H&E: Hematoxylin and eosin
IHC: Immunohistochemistry staining
Penh: The enhanced pause
qRT-PCR: Quantitative real-time RT-PCR
VEGF: Vascular endothelial growth factor.
Acknowledgments
This research was supported in part by the National Sci-
ence Council Grant NSC-98-2313-B-005-012, the Council of
Agriculture Grant COA-97-6.2.1-U1(9), and the Ministry of
Education, Taiwan, under the Aiming Top University Plan
(ATU-101-S0508). The authors would like to express their
gratitude to these entities.
References
[1] H.-H. Lin, C.-W. Tsai, F.-P. Chou et al., “Andrographolide down-
regulates hypoxia-inducible factor-1𝛼 in human non-small cell
lung cancer A549 cells,” Toxicology and Applied Pharmacology,
vol. 250, no. 3, pp. 336–345, 2011.
Evidence-Based Complementary and Alternative Medicine 7
[2] S.-S. Lin, K.-C. Lai, S.-C. Hsu et al., “Curcumin inhibits the
migration and invasion of human A549 lung cancer cells
through the inhibition ofmatrixmetalloproteinase-2 and -9 and
Vascular Endothelial Growth Factor (VEGF),” Cancer Letters,
vol. 285, no. 2, pp. 127–133, 2009.
[3] A. Puri, R. Saxena, R. P. Saxena, K. C. Saxena, V. Srivastava,
and J. S. Tandon, “Immunostimulant agents from Andrographis
paniculata,” Journal of Natural Products, vol. 56, no. 7, pp. 995–
999, 1993.
[4] J. Melchior, S. Palm, and G.Wikman, “Controlled clinical study
of standardized Andrographis paniculata extract in common
cold-a pilot trial,” Phytomedicine, vol. 34, pp. 315–318, 1996.
[5] G. Zhi-ling, Z. Hua-yue, and Z. Xin-hua, “An experimental
study of themechanism ofAndrographis paniculata nees (APN)
in alleviating the Ca2+-overloading in the process of myocar-
dial ischemie reperfusion,” Journal of Tongji Medical University,
vol. 15, no. 4, pp. 205–208, 1995.
[6] V. Thamlikitkul, S. Theerapong, P. Boonroj et al., “Efficacy of
Andrographis paniculata, nees for pharyngotonsillitis in adults,”
Journal of theMedical Association ofThailand, vol. 74, no. 10, pp.
437–442, 1991.
[7] J. T. Coon and E. Ernst, “Andrographis paniculata in the
treatment of upper respiratory tract infections: a systematic
review of safety and efficacy,” Planta Medica, vol. 70, no. 4, pp.
293–298, 2004.
[8] Y.-C. Shen, C.-F. Chen, and W.-F. Chiou, “Andrographolide
prevents oxygen radical production by human neutrophils:
possiblemechanism(s) involved in its anti-inflammatory effect,”
British Journal of Pharmacology, vol. 135, no. 2, pp. 399–406,
2002.
[9] Y. Tan, K. Chiow, D. Huang, and S. Wong, “Andrographolide
regulates epidermal growth factor receptor and transferrin
receptor trafficking in epidermoid carcinoma (A-431) cells:
research paper,” British Journal of Pharmacology, vol. 159, no. 7,
pp. 1497–1510, 2010.
[10] C.-G. Jiang, J.-B. Li, F.-R. Liu, T. Wu, M. Yu, and H.-M. Xu,
“Andrographolide inhibits the adhesion of gastric cancer cells to
endothelial cells by blocking E-selectin expression,” Anticancer
Research, vol. 27, no. 4 B, pp. 2439–2447, 2007.
[11] N. P. Trivedi, U. M. Rawal, and B. P. Patel, “Hepatoprotec-
tive effect of andrographolide against hexachlorocyclohexane-
induced oxidative injury,” Integrative Cancer Therapies, vol. 6,
no. 3, pp. 271–280, 2007.
[12] C. Satyanarayana, D. S. Deevi, R. Rajagopalan, N. Srinivas,
and S. Rajagopal, “DRF 3188 a novel semi-synthetic analog
of andrographolide: cellular response to MCF 7 breast cancer
cells,” BMC Cancer, vol. 4, article 26, 2004.
[13] H.-L. Chen, L.-C. Wang, C.-H. Chang et al., “Recombinant
porcine lactoferrin expressed in the milk of transgenic mice
protects neonatal mice from a lethal challenge with enterovirus
type 71,” Vaccine, vol. 26, no. 7, pp. 891–898, 2008.
[14] C.-J. Shen, W. T. K. Cheng, S.-C. Wu et al., “Differential
differences in methylation status of putative imprinted genes
among cloned swine genomes,” PLoS ONE, vol. 7, no. 2, Article
ID e32812, 2012.
[15] Y.-J. Chen, C.-Y.Wu,C.-C. Chang, C.-J.Ma,M.-C. Li, andC.-M.
Chen, “Nuclear Kru¨ppel-like factor 4 expression is associated
with human skin squamous cell carcinoma progression and
metastasis,” Cancer Biology &Therapy, vol. 7, no. 5, pp. 777–782,
2008.
[16] Y.-T. Tung, H.-L. Chen, C.-W. Lai, C.-J. Shen, Y.-W. Lai, and
C.-M. Chen, “Curcumin reduces pulmonary tumorigenesis
in vascular endothelial growth factor (VEGF)-overexpressing
transgenic mice,” Molecular Nutrition and Food Research, vol.
55, no. 7, pp. 1036–1043, 2011.
[17] H.-L. Chen, Y.-W. Lai, C.-S. Chen et al., “Probiotic Lactobacillus
casei expressing human lactoferrin elevates antibacterial activ-
ity in the gastrointestinal tract,” BioMetals, vol. 23, no. 3, pp.
543–554, 2010.
[18] T.-C. Tsai, W. Lin, S.-H. Yang et al., “Granzyme G is expressed
in the two-cell stage mouse embryo and is required for the
maternal-zygotic transition,” BMC Developmental Biology, vol.
10, article 88, 2010.
[19] C.-M. Chen, C.-M. Hung, C.-C. Yeh et al., “Gingyo-san
enhances immunity and potentiates infectious bursal disease
vaccination,” Evidence-Based Complementary and Alternative
Medicine, vol. 2011, Article ID 238208, 10 pages, 2011.
[20] C.-C. Yen, C.-Y. Lin, K.-Y. Chong et al., “Lactoferrin as a
natural regimen for selective decontamination of the digestive
tract: recombinant porcine lactoferrin expressed in the milk of
transgenicmice protects neonates from pathogenic challenge in
the gastrointestinal tract,” Journal of Infectious Diseases, vol. 199,
no. 4, pp. 590–598, 2009.
[21] J. Y. Chen, H. L. Chen, and J. C. Cheng, “A Chinese
herbal medicine, Gexia-Zhuyu Tang (GZT), prevents
dimethylnitrosamine-induced liver fibrosis through
inhibition of hepatic stellate cells proliferation,” Journal of
Ethnopharmacology, vol. 142, pp. 811–818, 2012.
[22] S.-C. Wu, H.-L. Chen, C.-C. Yen et al., “Recombinant porcine
lactoferrin expressed in the milk of transgenic mice enhances
offspring growth performance,” Journal of Agricultural and Food
Chemistry, vol. 55, no. 12, pp. 4670–4677, 2007.
[23] V. L. Capelozzi, “Role of immunohistochemistry in the diagno-
sis of lung cancer,” Jornal Brasileiro de Pneumologia, vol. 35, no.
4, pp. 375–382, 2009.
[24] H. M. Chang, Pharmacology and Applications of Chinese Mate-
ria Medica, vol. 2, World Scientific Publishing, Singapore, 1987.
[25] S. S. Handa andA. Sharma, “Hepatoprotective activity of andro-
grapholide against galactosamine and paracetamol intoxication
in rats,” Indian Journal of Medical Research Section B, vol. 92, pp.
284–292, 1990.
[26] R. Ajaya Kumar, K. Sridevi, N. Vijaya Kumar, S. Nanduri, and
S. Rajagopal, “Anticancer and immunostimulatory compounds
from Andrographis paniculata,” Journal of Ethnopharmacology,
vol. 92, no. 2-3, pp. 291–295, 2004.
[27] T.Matsuda, M. Kuroyanagi, S. Sugiyama, K. Umehara, A. Ueno,
and K. Nishi, “Cell differentiation-inducing diterpenes from
Andrographis paniculata NEES,” Chemical and Pharmaceutical
Bulletin, vol. 42, no. 6, pp. 1216–1225, 1994.
[28] S. Rajagopal, R. A. Kumar, D. S. Deevi, C. Satyanarayana, and R.
Rajagopalan, “Andrographolide, a potential cancer therapeutic
agent isolated from Andrographis paniculata,” Journal of Exper-
imental Therapeutics and Oncology, vol. 3, no. 3, pp. 147–158,
2003.
[29] D.W.Wang andH. Y. Zhao, “Prevention of atherosclerotic arte-
rial stenosis and restenosis after angioplasty with Andrographis
paniculata nees and fish oil. Experimental studies of effects and
mechanisms,” Chinese Medical Journal, vol. 107, no. 6, pp. 464–
470, 1994.
[30] S. R. Jada, A. S. Hamzah, N. H. Lajis, M. S. Saad, M. F. G.
Stevens, and J. Stanslas, “Semisynthesis and cytotoxic activities
of andrographolide analogues,” Journal of Enzyme Inhibition
and Medicinal Chemistry, vol. 21, no. 2, pp. 145–155, 2006.
8 Evidence-Based Complementary and Alternative Medicine
[31] M.-D. Shi, H.-H. Lin, Y.-C. Lee, J.-K. Chao, R.-A. Lin, and J.-H.
Chen, “Inhibition of cell-cycle progression in human colorectal
carcinoma Lovo cells by andrographolide,” Chemico-Biological
Interactions, vol. 174, no. 3, pp. 201–210, 2008.
[32] L. Ellis,H.Hammers, andR. Pili, “Targeting tumor angiogenesis
with histone deacetylase inhibitors,”Cancer Letters, vol. 280, no.
2, pp. 145–153, 2009.
[33] N. Ferrara, “VEGF and the quest for tumour angiogenesis
factors,”Nature Reviews Cancer, vol. 2, no. 10, pp. 795–803, 2002.
[34] F. Zhao, E.-Q. He, L.Wang, and K. Liu, “Anti-tumor activities of
andrographolide, a diterpene from Andrographis paniculata, by
inducing apoptosis and inhibiting VEGF level,” Journal of Asian
Natural Products Research, vol. 10, no. 5-6, pp. 467–473, 2008.
Submit your manuscripts at
http://www.hindawi.com
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Obesity
Journal of
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013
The Scientific 
World Journal
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Mediators
inflaMMation
of
ISRN 
Anesthesiology
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Computational and 
Mathematical Methods 
in Medicine
ISRN 
Allergy
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
BioMed Research 
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
International Journal of
Endocrinology
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2013
ISRN 
Addiction
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com
Oncology
Journal of
Volume 2013
ISRN 
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Oxidative Medicine and 
Cellular Longevity
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Clinical &
Developmental
Immunology
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
ISRN 
Biomarkers
PPAR
Resea rch
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
